Publications by authors named "Ted Underiner"

Claim this Profile
I
Improvement of inhibitor identification for heat shock protein 90α by utilizing a red-shifted fluorescence polarization probe.
Jie Qian, Beverly P Holskin, Jay Theroff, Ted Underiner, Sheryl L Meyer

Assay Drug Dev Technol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
Robert L Hudkins, Nadine C Becknell, Allison L Zulli, Ted L Underiner, Thelma S Angeles

J Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.
Craig A Zificsak, Diane E Gingrich, Henry J Breslin, Derek D Dunn, Karen L Milkiewicz, Ted L Underiner

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
Linda R Weinberg, Mark S Albom, Thelma S Angeles, Henry J Breslin, Diane E Gingrich, Ted L Underiner

Bioorg Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Karen L Milkiewicz, Lisa D Aimone, Mark S Albom, Thelma S Angeles, Hong Chang, Ted L Underiner

Bioorg Med Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.
Craig A Zificsak, Jay P Theroff, Lisa D Aimone, Thelma S Angeles, Mark S Albom, Ted L Underiner

Bioorg Med Chem Lett· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.
Linda R Weinberg, Mark S Albom, Thelma S Angeles, Jean Husten, Joseph G Lisko, Ted L Underiner

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Craig A Zificsak, Jay P Theroff, Lisa D Aimone, Mark S Albom, Thelma S Angeles, Ted L Underiner

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.
Gregory R Ott, Rabindranath Tripathy, Mangeng Cheng, Robert McHugh, Andrew V Anzalone, Ted L Underiner

ACS Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
8
8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.
Robert L Hudkins, Allison L Zulli, Ted L Underiner, Thelma S Angeles, Lisa D Aimone

Bioorg Med Chem Lett· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Karen L Milkiewicz, Linda R Weinberg, Mark S Albom, Thelma S Angeles, Mangeng Cheng, Ted L Underiner

Bioorg Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.
Ted L Underiner, Torsten Herbertz, Sheila J Miknyoczki

Anticancer Agents Med Chem· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
Ted L Underiner, Bruce Ruggeri, Lisa Aimone, Mark Albom, Thelma Angeles

Bioorg Med Chem Lett· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Reddeppareddy Dandu, Allison L Zulli, Edward R Bacon, Ted Underiner, Candy Robinson

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
Weihua Wan, Mark S Albom, Lihui Lu, Matthew R Quail, Nadine C Becknell, Ted L Underiner

Blood· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.
Jodi A Laakso, Robert Raulli, Gail E McElhaney-Feser, Paul Actor, Ted L Underiner

J Nat Prod· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Syntheses of C12,N13 heterocyclic bridged fused indenopyrrolocarbazoles.
Ted L Underiner, John P Mallamo, Jasbir Singh

J Org Chem· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis